BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.82 -0.37 (-4.52%) Market Cap: 1.62 Bil Enterprise Value: 2.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

BioCryst Pharmaceuticals Inc Conference Call Transcript

Dec 15, 2022 / 01:30PM GMT
Release Date Price: $10.81 (-3.22%)
Operator

Good day, and welcome to the BioCryst conference call. (Operator Instructions) Please note today's event is being recorded. I would now like to turn the conference over to John Bluth at BioCryst. Please go ahead.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - Chief Communications Officer

Thank you. Good morning, and thanks for joining our call this morning. A press release issued earlier today is available on our website and participating with me today on the conference call are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; Chief R&D Officer, Dr. Helen Thackary; Chief Medical Officer, Dr. Ryan Arnold; and Chief Development Officer, Dr. Bill Sheridan. Following our remarks, we'll answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements are subject to unknown risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot